JP2001511000A - アンチセンスオリゴヌクレオチドの製造方法 - Google Patents
アンチセンスオリゴヌクレオチドの製造方法Info
- Publication number
- JP2001511000A JP2001511000A JP53253398A JP53253398A JP2001511000A JP 2001511000 A JP2001511000 A JP 2001511000A JP 53253398 A JP53253398 A JP 53253398A JP 53253398 A JP53253398 A JP 53253398A JP 2001511000 A JP2001511000 A JP 2001511000A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- antisense
- sequences
- cells
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. アンチセンスオリゴヌクレオチドまたはその誘導体の製造方法であって、 -標的核酸を選択し、必要に応じてその配列を解明し、 -アンチセンスオリゴヌクレオチドを生成し、但し -該オリゴヌクレオチドは少なくとも8個の残基を含み、 -該オリゴヌクレオチドはシトシン塩基に対しそれぞれ3個の水素結合を形 成することができる最大で12のエレメントを含むものとし、 -該オリゴヌクレオチドは、標的分子内で4個の連続シトシン塩基(CCCC) とそれぞれ3個の水素結合を形成できる4個以上の連続エレメントを含ま ず、あるいはGGGGの4個以上の連続エレメントを含まないものとし、 -また該オリゴヌクレオチドは、標的分子内で3個の連続シトシン塩基(CCC) とそれぞれ3個の水素結合を形成できる3個以上の連続エレメントを2シ リーズ以上含まず、あるいはGGGの3個の連続エレメントを2シリーズ以 上含まないものとし、 -残基あたり2個の水素結合を標的分子と形成する残基(2H-結合-R)と残 基あたり3個の水素結合を標的分子と形成する残基(3H-結合-R)との間 の比が以下の関係に支配され、 -そして上記のように生成されるオリゴヌクレオチドをそれ自体公知の方法で合 成する、 ステップを含む前記方法。 2. 生成されたオリゴヌクレオチドが以下の条件 を満たす請求項1に記載の方法。 3. 生成されるオリゴヌクレオチドが、天然のオリゴまたはポリヌクレオチドよ り高いヌクレアーゼ耐性を有するように修飾される請求項1または2に記載の方 法。 4. 生成されたオリゴヌクレオチドが、オリゴヌクレオチドの塩基、糖または結 合において、好ましくは、ホスホロチオエート(S-ODN)ヌクレオチド間結合、 及び/またはメチルホスホネートヌクレオチド間結合、N'3→P5'ホスホルアミデ ート結合、ペプチド結合、または糖部分の2'-メトキシエトキシ修飾、または塩 基の修飾により修飾される請求項3に記載の方法。 5. オリゴヌクレオチドが少なくとも2種の異なる種類の修飾を有する請求項3 及び/または4に記載の方法。 6. オリゴヌクレオチドが、葉酸、ホルモン、例えばステロイドホルモンもしく はコルチコステロイド、ペプチド、プロテオグリカン、グリコリピド、またはホ スホリピドに共有結合されるか、混合されていることにより、オリゴヌクレオチ ドが葉酸、ホルモン、例えばステロイドホルモンまたはコルチコステロイド、ま たはそれらの誘導体と反応させられている請求項1〜5のいずれか1項に記載の方 法。 7. オリゴヌクレオチドが図4に示されたものであることを除き請求項1〜6のい ずれか1項に記載のアンチセンスオリゴヌクレオチドまたはその誘導体。 8. 4個以上の連続したグアノシン(NaGGGGNb)またはイノシン(NaIIIINb)残 基を含まず、かつ前記オリゴヌクレオチドは3個以上の連続したグアノシン残基 を2シリーズ(NaGGGNcGGGNb)以上含まず、かつ3個以上の連続したイノシン残基 を2シリーズ(NaIIINcIIINb)以上含まない(但し、式中、Na、Nb、Ncは独立し て 0〜20の残基を有するヌクレオチドまたはオリゴヌクレオチドまたはその誘導体 を表す)請求項7に記載のオリゴヌクレオチドまたは誘導体。 9. 少なくとも10個、最大で24個のエレメントあたり2個または3個の水素結合 を形成することができるエレメントを含む請求項7及び/又は8に記載のオリゴ ヌクレオチドまたは誘導体。 10. オリゴヌクレオチドの塩基、糖またはリン酸部分に修飾を有する請求項7 〜9のいずれか1項に記載のオリゴヌタレオチドまたは誘導体。 11. 修飾は、ホスホロチオエート(S-ODN)ヌクレオチド間結合、及び/また はメチルホスホネートヌクレオチド間結合、N'3→P5'ホスホルアミデート結合、 ペプチド結合あるいは糖の2'-メトキシエトキシ修飾あるいは塩基の修飾である 請求項7〜10のいずれか1項に記載のオリゴヌクレオチドまたは誘導体。 12. 葉酸、ホルモン、ステロイドホルモン、例えばエストロゲン、プロゲステ ロン、コルチコステロイド、ミネラルコルチコイド、ペプチド、プロテオグリカ ン、グリコリピド、ホスホリピド及びそれらの誘導体と結合されるか混合された 請求項7〜11のいずれか1項に記載のオリゴヌクレオチドまたは誘導体。 13. TGF-β1に対するアンチセンスオリゴヌクレオチドは、図3の配列41〜73 を含み、遺伝子p53に対するアンチセンスオリゴヌクレオチドは、図3の配列74 〜106を含み、junBに対するアンチセンスオリゴヌクレオチドは、図3の配列154 〜172を含み、junDに対するアンチセンスオリゴヌクレオチドは、図3の配列173 〜203を含み、erbB-2遺伝子に対するアンチセンスオリゴヌクレオチドは、図3 の配列298〜380を含み、c-fos遺伝子に対するアンチセンスオリゴヌクレオチド は、図3の配列476〜506を含み、遺伝子TGF-β2に対するアンチセンスオリゴヌ クレオチドは、図3の配列519〜556を含み、遺伝子rbに対するアンチセンスオリ ゴヌクレオチドは、図3の配列597〜641及び図5の1273〜1764を含む請 求項7〜12のいずれか1項に記載のオリゴヌクレオチドまたは誘導体。 14. 特に、肝細胞、腎臓細胞、破骨細胞、骨芽細胞及び/またはケラチン合成 細胞及び/または血液系細胞、例えば骨髄幹細胞及び/または赤血球及び白血球 の始原細胞の初代細胞の細胞増殖に影響を与えるために遺伝子p53、rb、junD、j unB、TGF-β1、TGF-β2の阻害のための組成物または医薬品の製造のための請求 項7〜13のいずれか1項に記載のオリゴヌクレオチドまたは誘導体を含む組成物 。 15. 添加剤とともに請求項7〜13のいずれか1項に記載のオリゴヌクレオチド または誘導体を含む組成物。 16. 本発明のオリゴヌクレオチドは、腫瘍、低増殖状態、過剰増殖状態、変性 疾患、神経性変性疾患、虚血症、免疫系の疾患及び/または感染症、及び/また は代謝機能異常の予防及び/または治療用の医薬の製造のための請求項7〜13の いずれか1項に記載のオリゴヌクレオチドの使用。 17. 遺伝子機能の分析または医薬標的評価のための請求項7〜13のいずれか1 項に記載のオリゴヌクレオチドの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97101531A EP0856579A1 (en) | 1997-01-31 | 1997-01-31 | An antisense oligonucleotide preparation method |
EP97101531.8 | 1997-01-31 | ||
PCT/EP1998/000497 WO1998033904A2 (en) | 1997-01-31 | 1998-01-30 | An antisense oligonucleotide preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001511000A true JP2001511000A (ja) | 2001-08-07 |
Family
ID=8226428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53253398A Pending JP2001511000A (ja) | 1997-01-31 | 1998-01-30 | アンチセンスオリゴヌクレオチドの製造方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6972171B1 (ja) |
EP (4) | EP0856579A1 (ja) |
JP (1) | JP2001511000A (ja) |
AT (1) | ATE428780T1 (ja) |
AU (1) | AU6617898A (ja) |
DE (1) | DE69840748D1 (ja) |
ES (1) | ES2323252T3 (ja) |
WO (1) | WO1998033904A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007518709A (ja) * | 2003-12-19 | 2007-07-12 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
WO2009071680A3 (en) * | 2007-12-07 | 2009-07-23 | Santaris Pharma As | Rna antagonist compounds for the modulation of mcl-1 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
EP1055366A1 (en) * | 1999-05-26 | 2000-11-29 | Boehringer Ingelheim International GmbH | Use of transgenic mice lacking jun-b expression in the myeloid lineage |
EP1296643A4 (en) * | 1999-09-17 | 2005-07-27 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF TGF-BETA EXPRESSION |
GB9929487D0 (en) * | 1999-12-15 | 2000-02-09 | Zeneca Ltd | Antisense oligonucleotides |
US7521216B2 (en) | 1999-12-29 | 2009-04-21 | Verenium Corporation | Nitrilases and methods for making and using them |
US7300775B2 (en) | 1999-12-29 | 2007-11-27 | Verenium Corporation | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents |
AU2013200739B2 (en) * | 1999-12-29 | 2015-08-27 | Basf Enzymes Llc | Nitrilases |
US6613567B1 (en) * | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
DE10048091A1 (de) * | 2000-09-28 | 2002-04-25 | Ernst Bayer | Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor |
EP1379686B1 (en) * | 2000-12-01 | 2012-09-05 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates |
AUPS078002A0 (en) * | 2002-02-27 | 2002-03-21 | Unisearch Limited | Dnazyme therapeutics |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
KR101032853B1 (ko) * | 2003-08-05 | 2011-05-06 | 에이브이아이 바이오파마 인코포레이티드 | 웨스트 나일 바이러스 감염을 치료하기 위한 약학적 조성물 |
EP2248895B8 (en) | 2003-12-19 | 2016-09-21 | Autotelic LLC | Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent |
TWI350373B (en) | 2004-01-23 | 2011-10-11 | Oncotherapy Science Inc | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators |
EP1722823A2 (en) * | 2004-02-27 | 2006-11-22 | Antisense Pharma GmbH | Pharmaceutical composition |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
ZA200709237B (en) | 2005-05-05 | 2009-04-29 | Antisense Pharma Gmbh | Dosage of oligonucleotides |
WO2006121208A1 (en) * | 2005-05-12 | 2006-11-16 | Oncotherapy Science, Inc. | Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility |
US8093369B2 (en) * | 2005-10-11 | 2012-01-10 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | Compositions for silencing the expression of VDAC1 and uses thereof |
ATE508191T1 (de) | 2006-11-01 | 2011-05-15 | Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase |
US9217164B2 (en) | 2007-03-01 | 2015-12-22 | Basf Enzymes Llc | Nitrilases, nucleic acids encoding them and methods for making and using them |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
PE20121495A1 (es) * | 2009-07-30 | 2012-11-19 | Antisense Pharma Gmbh | Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta |
WO2011088148A1 (en) * | 2010-01-12 | 2011-07-21 | Isis Pharmaceuticals, Inc. | Modulation of transforming growth factor-beta 1 expression |
US20130034599A1 (en) | 2010-01-19 | 2013-02-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
JP2013531981A (ja) | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
EP3164113B1 (en) | 2014-06-04 | 2019-03-27 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
EP3204499A4 (en) | 2014-10-06 | 2018-04-25 | Exicure, Inc. | Anti-tnf compounds |
WO2017138924A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Compositions and methods for treating pancreatic cancer |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871861A (en) * | 1987-07-06 | 1989-10-03 | Olin Corporation | Substituted 5-amidotetrazoles |
US5221620A (en) * | 1987-10-06 | 1993-06-22 | Oncogen | Cloning and expression of transforming growth factor β2 |
US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
JP2823959B2 (ja) * | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
WO1994025588A2 (en) * | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
AU6984594A (en) * | 1993-06-15 | 1995-01-17 | Hun Taeg Chung | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
WO1995002422A1 (en) * | 1993-07-12 | 1995-01-26 | Weltman Joel K | Method for conjugating nucleotides and nucleosides to disulfide-, maleimide-, and thiol-containing compounds |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5744362A (en) * | 1994-05-31 | 1998-04-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
WO1996031600A1 (en) * | 1995-04-03 | 1996-10-10 | Hybridon, Inc. | Method of modulating gene expression without depleting complement |
-
1997
- 1997-01-31 EP EP97101531A patent/EP0856579A1/en not_active Withdrawn
-
1998
- 1998-01-30 DE DE69840748T patent/DE69840748D1/de not_active Expired - Lifetime
- 1998-01-30 WO PCT/EP1998/000497 patent/WO1998033904A2/en active Application Filing
- 1998-01-30 JP JP53253398A patent/JP2001511000A/ja active Pending
- 1998-01-30 EP EP98908022A patent/EP1012267B1/en not_active Expired - Lifetime
- 1998-01-30 US US09/341,700 patent/US6972171B1/en not_active Expired - Lifetime
- 1998-01-30 EP EP07107328A patent/EP1889911A3/en not_active Withdrawn
- 1998-01-30 AU AU66178/98A patent/AU6617898A/en not_active Abandoned
- 1998-01-30 AT AT98908022T patent/ATE428780T1/de active
- 1998-01-30 EP EP08171099A patent/EP2028274A3/en not_active Withdrawn
- 1998-01-30 ES ES98908022T patent/ES2323252T3/es not_active Expired - Lifetime
-
2004
- 2004-11-10 US US10/984,919 patent/US7563778B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007518709A (ja) * | 2003-12-19 | 2007-07-12 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
JP4871732B2 (ja) * | 2003-12-19 | 2012-02-08 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
WO2009071680A3 (en) * | 2007-12-07 | 2009-07-23 | Santaris Pharma As | Rna antagonist compounds for the modulation of mcl-1 |
Also Published As
Publication number | Publication date |
---|---|
EP2028274A2 (en) | 2009-02-25 |
WO1998033904A3 (en) | 1999-05-14 |
US7563778B2 (en) | 2009-07-21 |
EP1889911A2 (en) | 2008-02-20 |
EP1889911A3 (en) | 2008-06-11 |
AU6617898A (en) | 1998-08-25 |
EP1012267A2 (en) | 2000-06-28 |
ES2323252T3 (es) | 2009-07-09 |
EP2028274A3 (en) | 2012-06-13 |
DE69840748D1 (de) | 2009-05-28 |
US20050130927A1 (en) | 2005-06-16 |
WO1998033904A2 (en) | 1998-08-06 |
ATE428780T1 (de) | 2009-05-15 |
EP1012267B1 (en) | 2009-04-15 |
US6972171B1 (en) | 2005-12-06 |
EP0856579A1 (en) | 1998-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001511000A (ja) | アンチセンスオリゴヌクレオチドの製造方法 | |
TWI231312B (en) | Novel dumbbell decoy oligodeoxynucleotides and use thereof | |
KR101718297B1 (ko) | Hsf1-관련 질환을 치료하기 위한 유기 조성물 | |
JP2001500530A (ja) | キメラ及び交互のオリゴヌクレオチドを用いたras遺伝子のアンチセンス阻害 | |
JPH09506770A (ja) | c−erbBの発現が関与する疾患を予防及び治療するためのアンチセンス核酸 | |
JPH08512300A (ja) | ニューロン損傷、変性及び細胞壊死の予防及び/又は治療、並びに腫瘍の治療を目的とするアンチセンス核酸を含む医薬用組成物 | |
JP2003505080A (ja) | ヒトeg5の発現を阻害するためのオリゴヌクレオチド | |
EP1357184A2 (en) | Novel cis-element decoys useful as anti-tumor therapeutics | |
KR20060120048A (ko) | 세포 및/또는 조직 및/또는 질환 단계 특이적 의약품의제조 방법 | |
KR20000065690A (ko) | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 dna 및 그 제조방법 | |
JP2009541304A (ja) | 抗癌治療としてのオーロラキナーゼbのrna干渉媒介阻害およびその組み合わせ | |
Petch et al. | Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides | |
JP2002519048A (ja) | bcl−xLのオリゴヌクレオチド阻害剤 | |
Park et al. | Reduction in cyclin D1/Cdk4/retinoblastoma protein signaling by CRE-decoy oligonucleotide | |
JP2002501505A (ja) | ヒトHa−ras遺伝子断片に相補的な修飾アンチセンスヌクレオチド | |
Ojala | Muscle cell differentiation in vitro and effects of antisense oligodeoxyribonucleotides on gene expression of contractile proteins | |
Mora et al. | Regulation of expression of the early growth response gene‐1 (EGR‐1) in malignant and benign cells of the prostate | |
EP3998108A1 (en) | Antisense oligonucleotide capable of altering splicing of dux4 pre-mrna | |
KR102132222B1 (ko) | 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용 | |
JP7065778B2 (ja) | 炎症性障害を処置するための新規なアプローチ | |
US20040204374A1 (en) | Cis-element decoys useful as anti-tumor therapeutics | |
EP1181361A2 (en) | Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna | |
JPH11506601A (ja) | サイトカインシグナル伝達物質gp130mRNAに特異的なオリゴヌクレオチド | |
CN111471679A (zh) | 干预eif4h剪接亚型的寡聚核苷酸及其应用 | |
JPWO2004027061A1 (ja) | 抗増殖性疾患治療薬のスクリーニング法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080408 |